David S. Scott's Insider Trades & SAST Disclosures
David S. Scott's most recent trade in BlackLine Inc was a trade of 668 Common Stock done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David S. Scott.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BlackLine Inc | Scott J. Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 668 | 668 (0%) | 0% | 0 | Common Stock | |
| ADT Inc | David A. Scott | EVP, Chief People & Admin. Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 395,256 | 395,256 | - | - | Employee Stock Option (right to buy) | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.08 per share. | 23 Aug 2024 | 3,376 | 69,541 (0%) | 0% | 8.1 | 27,278 | Common Stock |
| Cedar Fair L.P. | David Scott Olivet | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 25,383 | 0 | - | - | Phantom Units | |
| Cedar Fair L.P. | David Scott Olivet | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 8,599 | 0 (0%) | 0% | - | Units of Limited Partner Interest | |
| Cedar Fair L.P. | David Scott Olivet | Director | Grant, award, or other acquisition of securities at price $ 54.35 per share. | 01 Jul 2024 | 1,373 | 8,599 (0%) | 0% | 54.4 | 74,623 | Units of Limited Partner Interest |
| Couchbase Inc | David C. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 6,494 | 28,027 | - | 0 | Common Stock | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.75 per share. | 07 Apr 2024 | 1,771 | 72,917 (0%) | 0% | 10.7 | 19,038 | Common Stock |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.62 per share. | 01 Apr 2024 | 1,855 | 74,688 (0%) | 0% | 11.6 | 21,555 | Common Stock |
| ADT Inc | David A. Scott | EVP, Chief People & Admin. Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 345,622 | 345,622 | - | - | Employee Stock Option (right to buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 48,572 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 43,572 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,955 | 46,617 (0%) | 0% | 28.8 | 56,304 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,701 | 44,916 (0%) | 0% | 28.8 | 48,989 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 02 Feb 2024 | 209 | 38,171 (0%) | 0% | 11.5 | 2,397 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 02 Feb 2024 | 209 | 37,962 (0%) | 0% | 28.5 | 5,954 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 209 | 4,375 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.45 per share. | 26 Jan 2024 | 16,413 | 47,566 (0%) | 0% | 25.4 | 417,653 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 26 Jan 2024 | 16,413 | 63,979 (0%) | 0% | 3.3 | 53,506 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 16,413 | 68,742 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 9,604 | 47,566 (0%) | 0% | 12.9 | 123,892 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.27 per share. | 26 Jan 2024 | 9,604 | 37,962 (0%) | 0% | 25.3 | 242,717 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 9,604 | 8,721 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 5,700 | 49,262 (0%) | 0% | 3.3 | 18,582 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,700 | 43,562 (0%) | 0% | 25.0 | 142,554 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,700 | 85,455 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,600 | 18,625 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,600 | 37,962 (0%) | 0% | 25.0 | 140,068 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 5,600 | 43,562 (0%) | 0% | 12.9 | 72,240 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 85,155 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 25 | 7,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 18,325 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 37,962 (0%) | 0% | 25 | 7,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 300 | 38,562 (0%) | 0% | 3.3 | 978 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 22 Jan 2024 | 28,750 | 37,962 (0%) | 0% | 22.7 | 652,254 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 28,750 | 31,250 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 22 Jan 2024 | 28,750 | 66,712 (0%) | 0% | 10.1 | 291,238 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 22 Jan 2024 | 5,416 | 72,128 (0%) | 0% | 11.5 | 62,122 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 5,416 | 4,584 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.24 per share. | 22 Jan 2024 | 5,416 | 66,712 (0%) | 0% | 22.2 | 120,437 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 500 | 37,962 (0%) | 0% | 25 | 12,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 22 Jan 2024 | 500 | 38,862 (0%) | 0% | 3.3 | 1,630 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 500 | 91,155 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 22 Jan 2024 | 400 | 38,362 (0%) | 0% | 12.9 | 5,160 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 400 | 24,225 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 400 | 38,462 (0%) | 0% | 25 | 10,000 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 42,109 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,147 | 37,962 (0%) | 0% | 20.4 | 84,599 | Common Stock |
| Cedar Fair L.P. | Scott Olivet David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,769 | 24,444 | - | - | Phantom Units | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.99 per share. | 23 Aug 2023 | 3,376 | 76,543 (0%) | 0% | 8.0 | 26,974 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| Couchbase Inc | David C. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 9,874 | 21,533 | - | 0 | Common Stock | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 21,820 | 79,919 (0%) | 0% | 0 | Common Stock | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 21,820 | 21,820 | - | - | Performance Stock Units | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.33 per share. | 01 Apr 2023 | 2,259 | 58,099 (0%) | 0% | 8.3 | 18,817 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 28,089 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 23,089 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,483 | 26,606 (0%) | 0% | 4.2 | 6,184 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,473 | 25,133 (0%) | 0% | 4.2 | 6,142 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| Cedar Fair L.P. | David Scott Olivet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 3,145 | 20,429 | - | - | Phantom Units | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 434 | 2,628 (0%) | 0% | - | Class A Common Stock | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 434 | 434 | - | - | Restricted Stock Units | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.04 per share. | 01 Jan 2023 | 151 | 2,477 (0%) | 0% | 14.0 | 2,120 | Class A Common Stock |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.01 per share. | 23 Aug 2022 | 4,111 | 60,358 (0%) | 0% | 6.0 | 24,707 | Common Stock |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Jul 2022 | 100,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Jul 2022 | 100,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2022 | 84,000 | 84,000 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2022 | 72,671 | 72,671 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Jul 2022 | 40,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2022 | 27,329 | 27,329 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2022 | 26,000 | 26,000 | - | - | Employee Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Jul 2022 | 10,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Couchbase Inc | David C. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 11,659 | 11,659 | - | 0 | Common Stock | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 22,866 | 64,469 (0%) | 0% | 0 | Common Stock | |
| Potbelly Corp | David Scott Daniels | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 22,865 | 22,865 | - | - | Performance Stock Units | |
| Alteryx Inc - Ordinary Sha... | Scott J. Davidson | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.21 per share. | 01 Mar 2022 | 2,280 | 33,013 (0%) | 0% | 63.2 | 144,119 | Class A Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 16,729 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.95 per share. | 28 Feb 2022 | 1,130 | 15,599 (0%) | 0% | 10.0 | 11,244 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 9,934 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 14,097 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.13 per share. | 09 Feb 2022 | 1,473 | 12,624 (0%) | 0% | 10.1 | 14,921 | Common Stock |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Alteryx Inc - Ordinary Sha... | Scott J. Davidson | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.50 per share. | 01 Jan 2022 | 3,767 | 35,293 (0%) | 0% | 60.5 | 227,904 | Class A Common Stock |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 434 | 868 | - | - | Restricted Stock Units | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 434 | 1,306 (0%) | 0% | - | Class A Common Stock | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.44 per share. | 01 Jan 2022 | 149 | 1,157 (0%) | 0% | 32.4 | 4,834 | Class A Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Dish Network Corp - Ordina... | David A. Scott | EVP & CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 44.21 per share. | 13 Sep 2021 | 500 | 616 (0%) | 0% | 44.2 | 22,105 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges